Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise
Grail shares fell about 50% to $50.21 in after-hours trading after its Galleri cancer blood test missed the main goal in a major UK trial. The study failed to show a statistically significant drop in late-stage cancers. Grail said it will release fuller data later this spring and extend trial follow-up. Investors are watching for U.S. regulatory and Medicare decisions.